Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12201222 | 0.96 | EPHX2 (0.67) | CNR1KDM4E | |
| SCHEMBL8704897 | 0.88 | CNR1 (0.82) | CNR1KDM4EALDH1A1HPGDTRPV1 | |
| SCHEMBL24134447 | 0.87 | CNR1 (0.76) | CNR1ALDH1A1HPGDTRPV1MEN1 | |
| SCHEMBL8541979 | 0.87 | EPHX2 (0.72) | CNR1KDM4EALDH1A1HPGDTRPV1 | |
| SCHEMBL8541977 | 0.87 | EPHX2 (0.72) | CNR1KDM4EALDH1A1HPGDTRPV1 | |
| SCHEMBL9964253 | 0.87 | CNR1 (0.85) | CNR1KDM4EALDH1A1HPGDTRPV1 | |
| SCHEMBL15456964 | 0.87 | CNR1 (0.79) | CNR1KDM4EALDH1A1HPGDTRPV1 | |
| SCHEMBL14849281 | 0.87 | CNR1 (0.85) | CNR1KDM4EALDH1A1HPGDTRPV1 | |
| SCHEMBL6286194 | 0.87 | CNR1 (0.85) | CNR1KDM4EALDH1A1HPGDTRPV1 | |
| SCHEMBL6286826 | 0.87 | CNR1 (0.85) | CNR1KDM4EALDH1A1HPGDTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174459-A1 | LIPID CONTAINING FORMULATIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-06-08 | — | — | US | disclosed |
| US-20200361854-A1 | LIPID CONTAINING FORMULATIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-11-19 | — | — | US | disclosed |
| US-20180065918-A1 | LIPID CONTAINING FORMULATIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-03-08 | — | — | US | disclosed |
| US-9663449-B2 | — | — | 2017-05-30 | — | — | US | disclosed |
| US-8034376-B2 | Lipid containing formulations | Alnylam Pharamaceticals, Inc. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20090023673-A1 | LIPID CONTAINING FORMULATIONS | BANK OF AMERICA, N.A. | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361854-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | CNR1 4299/4885KDM4E 3221/4885ALDH1A1 3971/4885 |
| US-20180065918-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | CNR1 4299/4885KDM4E 3221/4885ALDH1A1 3971/4885 |
| US-20230174459-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | CNR1 4299/4885KDM4E 3221/4885ALDH1A1 3971/4885 |
| US-20090023673-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | CNR1 4299/4885KDM4E 3221/4885ALDH1A1 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.